The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent

XL388 is a mammalian target of rapamycin (mTOR) kinase inhibitor. We demonstrated that XL388 inhibited survival and proliferation of renal cell carcinoma (RCC) cell lines (786-0 and A549) and primary human RCC cells. XL388 activated caspase-dependent apoptosis in the RCC cells. XL388 blocked mTOR co...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Xiong, Zuquan, Zang, Yiwen, Zhong, Shan, Zou, Lujia, Wu, Yishuo, Liu, Shenghua, Fang, Zujun, Shen, Zhoujun, Ding, Qiang, Chen, Shanwen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5444733/
https://ncbi.nlm.nih.gov/pubmed/28404914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15620
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak